Merck Expands Outsourcing With Zhejiang Huahai For HIV Finished Product Manufacturing
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal will create $20 million in annual revenue over five years for the company, an analyst projects.
You may also be interested in...
Merck Trials Manufacturing Agreement With China’s Huahai Pharmaceutical
SHANGHAI - Zhejiang Huahai Pharmaceutical and Merck have entered into a trial manufacturing services agreement, the Chinese firm announced
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.